CYP2A6 and lung carcinoma: Previous reports have indicated that the deletion of CYP2A6 (CYP2A6*4C) may reduce the risk of lung cancer [68–71], suggesting that people with CYP2A6*4C may not activate tobacco nitrosamines from smoking.